Researchers supported in part by the National Institutes of Health (NIH) have developed an advanced risk assessment model for Hypertrophic Cardiomyopathy, a common inherited heart condition that affects nearly one in 500 people worldwide and remains a leading cause of sudden cardiac death. The findings, published in JAMA, demonstrate that combining clinical history, advanced imaging, and blood biomarker analysis can significantly improve the prediction of adverse cardiac events in patients with HCM. The research was conducted through the large international Hypertrophic Cardiomyopathy Registry, which was initially funded by the National Heart, Lung, and Blood Institute (NHLBI).
Existing Risk Models Have Key Limitations
According to Christopher Kramer, one of the study’s principal investigators, current clinical guidelines primarily focus on predicting sudden cardiac death and often fail to assess broader cardiovascular complications associated with the disease. “Current risk prediction guidelines for hypertrophic cardiomyopathy are imperfect, as they predict only sudden cardiac death, and not heart failure or other fatal and nonfatal cardiac adverse events,” Kramer said. He added that the new research marks a major advancement because it integrates multiple assessment tools to provide more accurate and comprehensive risk prediction.
Understanding Hypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy occurs when the heart muscle becomes abnormally thick, making it harder for the heart to pump blood effectively.
The condition can:
*Block blood flow from the left ventricle
*Trigger life-threatening heart rhythm abnormalities
*Cause heart failure symptoms
*Increase the risk of sudden cardiac death
Because HCM is often inherited and many patients remain asymptomatic for years, early and accurate risk assessment is critical for improving patient outcomes.
Researchers Integrated Multiple Diagnostic Tools
To improve prediction accuracy, researchers incorporated several advanced assessment methods into the study, including:
*Detailed patient medical history questionnaires
*Blood biomarker testing
*Genetic analysis (genotyping)
*Contrast-enhanced cardiac magnetic resonance imaging (MRI)
The goal was to better predict a wide range of adverse outcomes, including:
*Sudden cardiac death
*Heart failure
*Nonfatal arrhythmias
*Need for implanted cardiac devices
*Heart transplantation
Large International Study Followed Patients for Seven Years
The study enrolled nearly 2,700 HCM patients across 44 medical centers in North America and Europe, all with expertise in cardiac imaging and hypertrophic cardiomyopathy treatment.
Researchers collected:
*Clinical and medical history data
*Blood samples for biomarker analysis
*Advanced cardiac imaging results
Participants were then monitored for an average of seven years.
The study identified several major predictors associated with fatal and nonfatal cardiac events, including:
*Heart muscle scarring detected through imaging
*Abnormal heart muscle structure and function
*Prior history of heart failure
*Elevated levels of NTproBNP, a key cardiac blood biomarker
Researchers also found that cardiac MRI imaging of the left ventricle, combined with biomarker testing, significantly improved prediction of sudden cardiac death risk.
Findings Could Transform HCM Management
The researchers concluded that integrating cardiac MRI and biomarker testing into routine risk assessments provides a much fuller and more accurate understanding of patient risk compared to existing methods. David Goff, acting director of NHLBI said the findings could substantially improve disease management and long-term patient care. “This study provides strong evidence for incorporating cardiac MRI and blood biomarkers into risk prediction for people with HCM,” Goff noted. He added that the condition carries significant morbidity and mortality, making advances in predictive medicine especially important.
NIH and NHLBI Continue Advancing Cardiovascular Research
The National Heart, Lung, and Blood Institute is a global leader in supporting research focused on heart, lung, blood, and sleep-related disorders. Meanwhile, the National Institutes of Health, part of the U.S. Department of Health and Human Services, continues to fund research aimed at improving the understanding, treatment, and prevention of both common and rare diseases. As reported by pharmabiz.com, the latest findings highlight the growing role of precision medicine, advanced imaging, and biomarker-based diagnostics in improving cardiovascular healthcare outcomes worldwide.